Search

Displaying results 3311 - 3320 of 8700 in total
  1. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.

  2. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). … [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  3. Target

    T-cell surface glycoprotein CD8

    go.drugbank.com/bio_entities/BE0010265
    TargetHumans

    Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). … Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs).

    Synonyms: MAL
  4. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is an effective inhibitor of platelet aggregation.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  5. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  6. Drug

    PF-06305591

    go.drugbank.com/drugs/DB12106
    Investigational

    Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).

  7. Drug

    PX-102

    go.drugbank.com/drugs/DB15416
    Investigational

    PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).

  8. Drug

    PF-05105679

    go.drugbank.com/drugs/DB15450
    Investigational

    PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).

  9. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S. … FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Other esmolol formulations are still available for use.[L43942] … The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule

    Synonyms: (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamateCategories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 Substrates